Serum proteomic, peptidomic and metabolomic profiles in myasthenia gravis patients during treatment with Qiangji Jianli Fang by Chunmei Wang et al.
Wang et al. Chinese Medicine 2012, 7:16
http://www.cmjournal.org/content/7/1/16RESEARCH Open AccessSerum proteomic, peptidomic and metabolomic
profiles in myasthenia gravis patients during
treatment with Qiangji Jianli Fang
Chunmei Wang1, Yonghai Lu1, Zhixi Chen2, Xiaobin Liu3, Huangquan Lin4, Hui Zhao2, Jinyan Chen2,
Yiuwa Kwan4 and Saiming Ngai1*Abstract
Background: Qiangji Jianli Fang (QJF) has been used for treatment of myasthenia gravis (MG) in China. However,
our understanding of the effects of QJF against MG at the molecular level is limited. This study aims to investigate
the effects of QJF treatment of MG patients on the protein, peptide and metabolite levels in serum.
Methods: High-throughput proteomic, peptidomic and metabolomic techniques were applied to investigate serum
samples from 21 healthy individuals and 47 MG patients before and after QJF treatment via two-dimensional gel
electrophoresis, matrix-assisted laser desorption/ionization time of flight mass spectrometry and liquid
chromatography Fourier transform mass spectrometry, respectively.
Results: After QJF treatment, the expression levels of peptides m/z 1865.019, 2021.128 and 1211.668 of
complement C3f increased (P= 0.004, P= 0.001 and P= 0.043, respectively), while that of peptide m/z 1739.931 of
component C4b decreased (P= 0.043), in the serum of MG patients. The levels of γ-aminobutyric acid (P= 0.000)
and coenzyme Q4 (P= 0.000) resumed their normal states.
Conclusion: QJF could inhibit the activity of the complement system and restore the normal levels of metabolites.Background
Myasthenia gravis (MG) is a chronic autoimmune
neuromuscular disorder, with an incidence rate of 3–30/
1,000,000 people per year [1]. MG patients can produce
autoantibodies, such as anti-acetylcholine receptor anti-
body (AChRAb) and anti-muscle-specific receptor tyro-
sine kinase antibody (MuSKAb) through their own
immune system to prevent muscle contraction, and
cause muscle weakness and fatigue [2]. Genetic factors
play an important role in MG [3]. In addition, infection
with viruses or bacteria, such as poliovirus and Escheri-
chia coli, may be involved in the pathogenesis of MG
[4,5]. Anticholinesterase drugs, non-specific immuno-
suppressants, thymectomy and plasmapheresis are the
main therapeutic approaches to MG [6-8]. However, the
above treatments have some serious side effects, such as
cardiac arrhythmia, osteoporosis and hypotension, and* Correspondence: smngai@cuhk.edu.hk
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reproduction in any medium, provided the orcan not inhibit the relapse of patients’ symptoms and
achieve complete remission [9]. Alternative treatments
with higher efficacy and fewer side effects are required.
Chinese medicine (CM) has been practiced for many
diseases, including cancer, cardiovascular disease, inflam-
mation and Parkinson's disease, owing to its long-term
efficacy and few side effects [10-14]. The mechanisms of
CM immunomodulatory activity have previously been
elucidated in several studies, revealing vital roles for
immune effector cells, cytokine production and antibody
production [15-18].
Qiangji Jianli Fang (QJF) is a CM prescription modified
from the Buzhong Yiqi decoction including Radix astrag-
ali, Radix codonopsis pilosulae, Atractylodes macroce-
phala, Radix angelicae sinensis, Cimicifugae rhizoma,
Radix bupleuri, Pericarpium citri reticulatae and Radix
glycyrrhizae [19]. Previous investigations have demon-
strated that QJF exhibits similar efficiency in MG patients
to prednisone, and plays long-term protective roles in
MG by decreasing the AchRAb level and changing
the expression of serum cytokines with fewer side effectstd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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as podocarpaside I in Actaea podocarpa and polysacchar-
ide in Angelica acutiloba kitagawa, show characteristic
effects on the complement system [22,23]. Herbs such as
R. bupleuri and R. glycyrrhizae are beneficial for auto-
immune diseases by inhibiting the production of serum
autoantibodies and total IgG (Table 1). However, our
understanding of the effects of QJF against MG at the
molecular level is limited.
Increased AChRAb and MuSKAb levels were detected
in sera from MG patients by enzyme-linked immuno-
sorbent assays [39]. Abnormal serum cytokine levels
were also detected [40-42]. In addition, analyses of blood
proteomic, peptidomic and metabolomic profiles have
been employed to elucidate the pathological mechanisms
of diseases and to evaluate the efficiency of drug treat-
ments [43,44]. Differentially expressed proteins, pep-
tides and metabolites in serum from MG patients have
been compared with those in healthy people by two-
dimensional gel electrophoresis (2-DE) and mass spec-
trometry [45-47]. However, no reports have shown the
changes in the serum proteomic, peptidomic and meta-
bolomic patterns after QJF treatment.
In this study, high-throughput proteomic, peptidomic
and metabolomic techniques were adopted to elucidate
the effects of QJF on MG patients using matrix-assisted
laser desorption/ionization time-of-flight mass spectrometry
(MALDI-TOF MS), 2-DE and liquid chromatography Fou-
rier transform mass spectrometry (LC-FTMS), respectively.
Methods
Herbs
QJF was produced by the First Affiliated Hospital of
Guangzhou University of Chinese Medicine from a
boiled water extraction of eight herb components as fol-
lows: 60 g of R. astragali, 30 g of R. codonopsis pilosulae,
15 g of A. macrocephala, 10 g of R. angelicae sinensis,
10 g of C. rhizoma, 10 g of R. bupleuri, 5 g of P. citri
reticulatae and 5 g of R. glycyrrhizae. Compared with
the herb levels in the Buzhong Yiqi decoction, QJF con-
tained decreased levels of P. citri reticulatae (5 g vs. 6 g)Table 1 Herbal components of QJF and their reported active
Herbs Acti
R. astragali Polysaccharides; flavonoid
R. codonopsis pilosulae Polysaccharide
A. macrocephala Glycoprotein
R. angelicae sinensis Sulfated polysaccharide
C. rhizoma Cycloartane glycosides; cy
R. bupleuri Bupleurum polysaccharid
Pericarpium citri reticulatae Synephrine
R. glycyrrhizae Glycyrrhiza polysaccharideand R. glycyrrhizae (5 g vs. 9 g R. glycyrrhizae preparata)
and increased levels of R. astragali (60 g vs. 18 g),
R. codonopsis pilosulae (30 g vs. 6 g Panax ginseng),
A. macrocephala (15 g vs. 9 g), R. angelicae sinensis
(10 g vs. 3 g), C. rhizoma (10 g vs. 6 g) and R. bupleuri
(10 g vs. 6 g). The herbs were purchased from Zhixin
Medicine Health Co. Ltd. (China) and identified by the
School of Chinese Pharmaceutical Science, Guangzhou
University of Chinese Medicine, China. For the extrac-
tion, the herbs were boiled in four volumes of water for
1 h, and the extraction step was repeated once. The two
extracts were mixed together for use.
Participants
This study was approved by Ethics Commitee of
Guangzhou University of Chinese Medicine, and all par-
ticipants provided informed consent according to institu-
tional guidelines. Peripheral blood samples were
obtained from 47 patients (18 males and 29 females;
average age: 40 years) diagnosed with MG in the First
Affiliated Hospital of Guangzhou University of Chinese
Medicine. All MG patients were confirmed by the neo-
stigmine test. According to the Osserman classification
[48], 4 patients were class I, 34 patients were class II (17
class IIa; 17 class IIb), 4 patients were class IV and 5
patients were class V. All the patients were treated with
QJF orally once per day for 2 months. Peripheral blood
samples from 21 healthy individuals (10 males and 11
females; average age: 34 years) were collected as controls.
Preparation of serum samples
Before and after the 2-month treatment, blood samples
were collected, allowed to clot at 4 °C overnight
and centrifuged at 1,000 × g for 10 min. The sera were
collected and frozen in aliquots for storage at −80 °C
until analysis.
Albumin/IgG depletion
A Qproteome Albumin/IgG Depletion Kit (Qiagen,
USA) was used for depletion of albumin and IgG from
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applied to a depletion spin column and the eluate was
collected by centrifugation at 500 × g for 10 s. The sam-
ples were desalted by acetone (Merck, Germany) precipi-
tation and resuspended in buffer comprising 7 M urea
(GE Healthcare, Sweden), 2 M thiourea (GE Healthcare,
UK), 2% (w/v) 3-[(3-cholamidopropyl)-dimethylammo-
nio]-1-propanesulfonate (CHAPS) (USB, Germany) and
1% (w/v) dithiothreitol (USB, Canada). Subsequently, the
samples were quantified using a PlusOne™ 2D Quant Kit
(GE Healthcare, Sweden) according to the manufac-
turer’s instructions.
Two-dimensional gel elctrophoresis
2-DE experiments were performed following the proto-
col of GE Healthcare Life Science with some modifica-
tions. Albumin/IgG-depleted sera (100 μg) were loaded
onto immobilized pH strips (pH 3–10) of 13 cm in
length. Isoelectric focusing was performed using an
Ettan™ IPGphor™ Isoelectric Focusing System (GE
Healthcare, Sweden) with a total voltage hours (Vhs) of
38890 Vhs. The IPG strips were sequentially equilibrated
in buffer (50 mM Tris–HCl, pH 8.8, 6 M urea, 30% (v/v)
glycerol, 2% (w/v) SDS, 0.002% (w/v) bromophenol blue)
containing dithiothreitol (10 mg/mL) and iodoacetamide
(25 mg/mL; GE Healthcare, UK) for 15 min before sep-
aration by 11% sodium dodecyl sulfate polyacrylamide
gel electrophoresis. The gels were silver-stained and
analyzed using ImageMaster™ 2D Platinum ver. 5.0 soft-
ware (GE Healthcare, Sweden). The experiment was
repeated three times. Differentially expressed protein
spots (≥ 1.5-fold) were excised. After in-gel digestion
with 20 ng/μL trypsin (Promega, USA), the peptides
were extracted with 2.5% trifluoroacetic acid (Sigma,
Germany) and 80% acetonitrile (ACN) (Merck, Ger-
many) for mass spectrometry.
Peptide capture
Peptides in serum were extracted using Dynabeads RPC
18 (Invitrogen Dynal AS, Norway) according to the
manufacturer’s instructions. Serum (50 μL) was added to
a vial containing 20 μL (0.25 mg) of Dynabeads and
incubated at room temperature for 5 min. Peptides were
eluted with 10 μL of 80% ACN for mass spectrometry.
Mass spectrometry
Peptide solution (1.5 μL) extracted from a 2D gel spot or
captured from serum was spotted onto a MALDI target
plate, followed by spotting of 0.5 μL of α-cyano-4
-hydroxy-cinnamic acid (Sigma, USA). Peptides with
the mass range m/z 700–4000 were detected using a
4700 MALDI-TOF/TOF mass spectrometer (Applied
Biosystems, USA) in the reflectron positive-ion mode
and accumulated from 2000 laser shots with accelerationof 20 kV. The MS spectra were internally calibrated
using porcine trypsin autolytic products (m/z 842.509,
1045.564, 1940.935 and 2211.104). The MS peaks (MH+)
were detected with a minimum S/N ratio of ≥ 20 and a
cluster area S/N threshold of ≥ 25 without smoothing or
raw spectrum filtering. Peptide precursor ions corre-
sponding to contaminants, including keratin and the
trypsin autolytic products, were excluded with a mass
tolerance of ± 0.2 Da. The filtered precursor ions with
a defined threshold (S/N ratio ≥ 50) were selected
for the MS/MS scan. Fragmentation of precursor ions
was performed using the MS/MS 1-kV positive mode
with collision-induced dissociation on and argon as the
collision gas. MS/MS spectra were accumulated from
3000 laser shots using default calibration with Glu-
Fibrinopeptide B (Applied Biosystems, USA). The MS/
MS peaks were detected for a minimum S/N ratio of ≥ 3
and a cluster area S/N threshold of ≥ 15 with smoothing.
Metabolomic analysis
Serum was transferred into an Eppendorf tube and
diluted three-fold (v/v) with ACN. The mixture was
shaken vigorously for 30 s. After centrifugation at
9,600 × g for 10 min at room temperature, the super-
natant was analyzed using a Dionex Ultimate 3000 2D
Nanoflow LC System (Bruker Daltonics Inc., USA)
coupled to an Apex Ultra 7.0 Hybrid Qh-FTMS (Bruker
Daltonics Inc., USA) equipped with an electrospray
ionization source. An Atlantis T3 3 μm column (2.1 mm
i.d. × 150 mm; Waters, USA) was used. The column was
maintained at 35 °C. The mobile phases A and B were
water with 0.1% formic acid (Sigma, USA) and ACN
with 0.1% formic acid, respectively. The gradient dur-
ation program was: 0–2 min, 5% B; 2–17 min, 5–95% B;
17–20 min, 95% B; and 20–21 min, 95–5% B. The flow
rate was 0.2 mL/min. The spectra were acquired over
the m/z 50–1000 range in the positive ion mode. The
capillary voltage and spray shield were set to 4200 and
3500 V, respectively. The dry gas was set to 6 L/min at a
temperature of 200 °C. The neb gas was set to 3 L/min.
Data processing
The MS and MS/MS data acquired by MALDI-TOF MS
were loaded into GPS Explorer™ software ver. 3.5
(Applied Biosystems, USA) and searched against the
NCBInr human database using the Mascot search engine
(Matrix Science, UK) for protein and peptide identifica-
tion. The following search parameters were used: monoi-
sotopic peptide mass (MH+); mass range, 700–4000 Da;
one missed cleavage per peptide; enzyme, trypsin (no en-
zyme was selected for serum peptide data searching);
taxonomy, human; pI, 0–14; precursor ion mass toler-
ance, 50 ppm; MS/MS fragment ion mass tolerance,
0.1 Da; and variable modifications, oxidation for
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peptide data searching). Known contaminant ions corre-
sponding to keratin and/or trypsin were excluded from
the peak lists before database searching. Protein score
was calculated automatically by Mascot search engine
based on the comparison of peptide masses and peptide
fragment ion masses to amino acid sequences in data-
base. The top ten hits for each protein search were
reported. Proteins with MOWSE scores above 70 and at
least four matched peptides were accepted as identified.
The spectra of the captured serum peptides were
imported to Markerview™ software ver. 1.2.0.6 (Applied
Biosystems/MDS SCIEX, USA) using the following spec-
tra processing options: mass tolerance, 50 ppm; mini-
mum required response, 200; and maximum number of
peaks, 20000.
LC-FTMS data were exported by Data Analysis ver.
4.0 software (Bruker Daltonics Inc., USA) and analyzed
by SIMCA-P ver. 12.0 software (Umetrics AB, Sweden).
The data were presented as the mean ± standard devi-
ation (SD). The significance of differences was evaluated
by Student's t-test using SPSS 13.0 for Windows software
(SPSS Inc., USA). P values less than 0.05 were consid-
ered statistically significant.
Results and discussion
In this study, three approaches were applied to investi-
gate the changes in the serum profiles of MG patients
during QJF treatment. The proteomic approach detects
serum proteins of> 20 kDa, the peptidomic approach
evaluates peptides with a mass range of 700–4000 Da
and the metabolomic approach investigates metabolites
of< 1000 Da. Although serum proteins, peptides and
metabolites can serve as biomarkers to indicate the pro-
gression of a diseased state, changes in the processed
products, such as peptides and metabolites, can be
more complementary to a certain diseased state and
drug treatment.
Serum proteomic profiles
Arbitrarily combined serum samples from healthy con-
trols and MG patients before and after QJF treatment
were prepared, respectively. Before the proteomic
analysis, most of the highly abundant proteins, such as
albumin and IgG, were depleted from the serum sam-
ples. 2-DE and MALDI-TOF MS were performed to
identify differentially expressed proteins in the serum
samples from the different groups.
In the 2-DE gels, ten differentially expressed spots
were detected in the serum of MG patients compared
with the healthy controls (Figure 1). Five proteins were
identified in these ten spots through MALDI-TOF MS and
NCBI database searches. Among them, α-2-macroglobulin,
gelsolin and hemopexin were downregulated (decreases of2.49-, 1.91- and 2.07-fold with P=0.002, 0.046 and 0.011,
respectively) while haptoglobin and haptoglobin-related
protein were upregulated (increases of 1.58- and 2.62-fold
with P=0.062 and 0.005, respectively) in the serum of MG
patients compared with healthy controls (Table 2), suggest-
ing immunoreactivity in the MG patients. In the serum of
ankylosing spondylitis patients, another autoimmune dis-
ease, haptoglobin and its precursor were reported to show
significant increases [49,50]. The similar results observed
in MG patients in the present study further confirm their
roles in the pathological process of autoimmune diseases.
α-2-macroglobulin is a carrier protein for hormones and
an inhibitor of proteolytic enzyme activities [51], and its
decrease induces abnormalities in protease metabolism in
MG patients. The decrease in hemopexin in the serum of
MG patients may reflect an anemic state during the
chronic process [52].
To evaluate the effects of QJF on MG patients, the
serum proteomic profiles of MG patients before and after
treatment were compared using the above method. How-
ever, no differentially expressed proteins were identified,
even in the five proteins listed above, indicating that QJF
cannot reverse the expression changes in these proteins.
Serum peptidomic profiles
The serum peptides of all samples were extracted using
Dynabeads and analyzed by MALDI-TOF MS. Around
278 peptides within the mass range of m/z 700–4000
were extracted from the raw spectra using the spectra
processing options described in the Methods section.
Through MarkerView™ ver. 1.2 software analysis, 16
peptides identified as six proteins showed significant
decreases (P< 0.05) in MG patients and seven peptides
changed their quantities after QJF treatment (P< 0.05)
(Table 3).
The expression levels of complement C3f peptides,
such as m/z 1777.922, 1865.019, 1934.125 and 2021.128,
were significantly decreased in MG patients, while the
expression of complement C3f peptides m/z 1865.019,
2021.128 and 1211.668 were increased after QJF treat-
ment (Table 3). Complement C3f is the released inactive
peptide from component C3 [53], suggesting that QJF
could increase the degradation of C3 and alleviate the
high level of this complement component in the blood
of MG patients.
The complement C3 level is correlated with the clin-
ical severity of AChRAb-positive generalized MG [54].
Suppressed anti-AChR IgG production and deposition of
attack complexes at the endplates were found in C3
(−/−) mice, which showed resistance to MG [55]. There-
fore, QJF could be beneficial to MG patients via degrad-
ation of complement component C3.
Peptide m/z 1739.931 of complement C4b decreased
after QJF treatment (Table 3). C4b is a part of C3-
Figure 1 2-DE gel patterns derived from healthy control and MG patient sera. Aliquots containing 100 μg of albumin/IgG-depleted proteins
extracted from the sera of healthy controls (left) and MG patients (right) were subjected to isoelectric focusing (total: 38890 Vhs) using 13-cm
strips (pH 3–10). The 2-DE gels were silver-stained. Differentially expressed proteins (> 1.5-fold) were labeled in the gels. The fold changes were
calculated from three replicates. The X-axis shows pI 3–10 and the Y-axis shows the molecular weight in kDa.
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ences the production of active C3b [56]. The mechanism
of the QJF effect on the immunoreactivity could involve
an increase in the degradation of complement C3 and a
decrease in the production of the active complement C3
fragment. These findings suggest that inhibition of com-
plement components is a potential therapeutic strategy
with high efficacy for autoimmune diseases, including
MG [7,57].
Kallidin II was decreased in MG patients (decrease of
1.442-fold compared with healthy controls), and
remained decreased even after QJF treatment (decrease
of 3.698-fold compared with untreated MG patients)
(P= 0.000) (Table 3). Kallidin is a pro-inflammatory kinin
peptide that acts as a stimulant for several inflammatory
cytokines, such as tumor necrosis factor, interleukin-1
and interleukin-6, and is involved in many physiolog-
ical and pathological processes [58]. Abnormal serumTable 2 Differentially expressed proteins in the serum profile






5 Haptoglobin-related protein P00739
a The ratio of the volume percentage (vol %) between MG patient and healthy con
b P values were calculated by Student’s t-test.cytokine levels were shown to be related to the patho-
genesis of MG [40]. The decrease in kallidin II after QJF
treatment may inhibit the stimulation of cytokines
and reduce the activity of inflammatory molecules in
MG patients.
Peptides belonging to α-fibrinogen precursor, fibrinoli-
gase and prothrombin were also detected in this study.
These proteins are involved in blood coagulation. Upon
QJF treatment, most of the peptides showed no change,
except for the increase in peptide m/z 1020.516
(P= 0.000) and the decrease in peptide m/z 2553.160
(P= 0.005). However, no studies have shown their asso-
ciations with MG.
Serum metabolomic profiles
In our previous study [47], nine differentially expressed
metabolites were identified in the serum of MG patients,








17 207 −2.49 0.002
10 90 −1.91 0.046
13 180 −2.07 0.011
12 134 1.58 0.062
10 148 2.62 0.005
trol.
Table 3 Differentially expressed peptides in the serum profiles of MG patients before and after QJF treatment
Protein name Peptide mass Sequence Patient (P) vs. healthy control(C) After (A) vs. Before (B) treatment
Change P value Fold change
(C/P)
Change P value Fold change
(B/A)
Complement C3f 1777.922 SKITHRIHWESASLL Down 0.000 1.808 - - -
1865.019 SSKITHRIHWESASLL Down 0.000 2.311 Up 0.004 0.582
1934.125 SKITHRIHWESASLLR Down 0.043 1.412 - - -
2021.128 SSKITHRIHWESASLLR Down 0.000 2.488 Up 0.001 0.364
1211.668 RIHWESASLL - - - Up 0.043 0.753
Component C4b 1625.975 NGFKSHALQLNNRQ Down 0.010 5.421 - - -
1739.931 NGFKSHALQLNNRQI Down 0.013 2.295 Down 0.043 1.567
Kallidin II 904.682 RPPGFSPF Down 0.003 1.442 Down 0.000 3.698
α-fibrinogen precursor 905.452 FLAEGGGVR Down 0.020 2.625 - - -
1020.516 DFLAEGGGVR Down 0.001 3.435 Up 0.000 0.381
1077.550 GDFLAEGGGVR Down 0.001 2.156 - - -
1206.605 EGDFLAEGGGVR Down 0.023 4.059 - - -
1350.655 SGEGDFLAEGGGVR Down 0.019 2.284 - - -
1465.701 DSGEGDFLAEGGGVR Down 0.041 3.008 - - -
2931.280 SSSYSKQFTSSTSYNRGDSTFESKSY Down 0.006 2.025 - - -
2553.160 SSSYSKQFTSSTSYNRGDSTFES - - - Down 0.005 1.409
Fibrinoligase 2602.337 AVPPNNSNAAEDDLPTVELQGVVPR Down 0.043 1.824 - - -
Prothrombin 1389.686 TSEYQTFFNPR Down 0.044 1.675 - - -
Note: “-”indicates that the peptide showed no differential expression.
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phosphate, bisnorcholic acid, chenodeoxycholylglycine,
coprocholic acid and cholylglycine. In the present study,
we compared the serum metabolic profiles in MG
patients before and after QJF treatment by LC-FTMS.
Eight metabolites with significant changes in abundance
after QJF treatment were identified (Table 4). The results
showed that the GABA level was increased after QJF
treatment. GABA has an inhibitory role in autoimmune
inflammation, and an inefficient GABA signaling systemTable 4 Serum metabolite profiles of MG patients before and
Metabolite Formula ± ppma
Be
γ-aminobutyric acid C4H9NO2 −71.7
Coenzyme Q4 C29H42O4 43.1 1
Taurallocholic acid C26H45NO7S −75.8
Dipalmitoylphosphatidic acid C35H69O8P 92.9
Phytosphingosine C18H39NO3 −2.3
5b-Cyprinolsulfate C27H48O8S −50.2
Thromboxane B2 C20H34O6 40
Biliverdin IX C33H34N4O6 3.6 2
aMass differences between the calculated and measured metabolite masses.
bMean peak areas of metabolites in patients before and after QJF treatment. SD de
cChanges are calculated as the difference in the median concentrations before and
dP values were calculated by Student’s t-test.may result in unchecked proinflammatory cytokine pro-
duction via the p38 MAPK pathway [59,60]. Therefore,
QJF could improve the deficiency status of GABA in the
serum of MG patients.
Coenzyme Q4 was a detected metabolite with
decreased expression after QJF treatment. Coenzyme Q4
is a member of the ubiquinone family. Ubiquinone and
ubiquinol have protective effects on serum low-density
lipoprotein from lipid peroxidation [61]. Another ubiquin-
one coenzyme, Q10, exerts anti-inflammatory propertiesafter QJF treatment
Peak area (Mean± SDb) % Changec P valued
fore therapy After therapy
10.2 ± 0.52 15.80 ± 0.81 54.9 0.000
2.28 ± 3.41 7.89 ± 0.89 −35.7 0.000
0.03 ± 0.17 6.72 ± 5.32 19016.7 0.000
0.19 ± 0.38 6.65 ± 2.35 3397.8 0.000
1.73 ± 1.53 19.11 ± 7.29 1004.8 0.000
0.38 ± 0.61 2.63 ± 2.01 591.9 0.000
1.13 ± 1.45 2.92 ± 1.91 158.3 0.000
2.71 ± 5.78 6.36 ± 3.54 −71.9 0.000
notes standard deviation.
after QJF treatment.
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no reports have suggested a function for coenzyme Q4
in serum, and the issue of whether it exerts anti-
inflammatory properties requires further investigation.
In addition to the above two metabolites, six other
metabolites also changed their quantities following QJF
treatment, although no changes were detected in MG
patients compared with normal healthy controls. Among
these metabolites, phytosphingosine and dipalmitoylpho-
sphatidic acid have anti-inflammatory effects [63,64].
The increased level of thromboxane B2, an inactive
product of thromboxane A2, may improve the high
coagulation state of MG patients, while the decrease in
biliverdin IX indicated less hemoglobin breakdown.
Interestingly, increases in taurallocholic acid and 5b-
cyprinolsulfate, two bile acids involved in fat processing,
were also detected. However, no studies have reported
their functions in autoimmune or inflammatory diseases.
Conclusion
QJF could inhibit the activity of the complement system
and resume the normal levels of metabolites in MG
patients. The findings of the present and previous stud-
ies suggest that QJF is an effective drug for treatment
of MG.
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